Novartis AG ADR (NVS)vsRevvity Inc. (RVTY)
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
RVTY
Revvity Inc.
$99.09
+7.36%
HEALTHCARE · Cap: $9.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1881% more annual revenue ($56.58B vs $2.86B). NVS leads profitability with a 23.9% profit margin vs 8.4%. RVTY appears more attractively valued with a PEG of 0.53. RVTY earns a higher WallStSmart Score of 63/100 (C+).
NVS
Buy51
out of 100
Grade: C-
RVTY
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Margin of Safety
+7.8%
Fair Value
$109.59
Current Price
$99.09
$10.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.1%
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
ROE of 3.2% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : RVTY
The primary concerns for RVTY are Return on Equity, P/E Ratio. A P/E of 42.1x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a declining stock while RVTY is a value play — different risk/reward profiles.
RVTY carries more volatility with a beta of 1.13 — expect wider price swings.
RVTY is growing revenue faster at 5.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
RVTY scores higher overall (63/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?